Oncology Drug Reference Sheet: Tivozanib
Darcy Burbage, DNP, RN, AOCN®, CBCN®
Voice
Description
On March 10, 2021, the U.S. Food and Drug Administration approved tivozanib (Fotivda®), an oral kinase inhibitor, for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies
ONS Drug Education
Short summaries of newly approved oncology-related therapies or drugs with new indications.
View All Drug Education